Core Insights - Lantheus Holdings, Inc. is set to present new data on two oncology radiodiagnostic agents at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, highlighting its commitment to improving patient outcomes through advanced radiopharmaceuticals [1][12]. Presentation Details - Oral presentations will include the optimized production and quality control of the FAP imaging agent [64Cu]LNTH-1363S, presented by Gengyang Yuan on June 24, 2025 [2]. - Poster presentations will cover topics such as the positive predictive value of 18F-Piflufolastat PET/CT in recurrent prostate cancer and the first clinical evaluation of 68Ga-LNTH-1363S for PET imaging [2]. Product Information - PYLARIFY® (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer, with a recommended dose of 333 MBq (9 mCi) [3][4]. - PYLARIFY has been utilized in over 500,000 scans across the U.S., making it the most ordered PSMA PET imaging agent [3]. Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, with nearly 70 years of experience in providing solutions that enhance disease detection and treatment [12].